Search clinical trials for: High Risk Myelodysplastic Syndromes (MDS)

Total 46798 results

M.D. Anderson Cancer Center

Completed

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Leukemia | Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Zhejiang Provincial Hospital of TCM

Unknown

Study on High-risk MDS Patients Based on RNA-seq Technology (MDS&RNA-seq)

MDS

China
University Of Perugia

Recruiting

Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

MDS and Allogeneic Stem Cell Transplantation

Italy
University Hospital, Brest

Recruiting

Biocollection in MyeloDysplastic Syndrome (P-MDS) (P-MDS)

Myelodysplastic Syndromes | Chromosome Abnormality | Acute Myeloid Leukemia With Multilineage Dysplasia | Myelodysplastic Syndrome With Ring Sideroblasts | Myelodysplastic Anemia | Myelodysplastic Syndrome With Isolated Del(5Q)

France
Orlucent, Inc
University Hospitals, Leicester; NHS Tayside; University of Dundee; NHS Greater... and other collaborators

Completed

Investigating the Clinical Utility of the MDS (OMS002_UK)

Melanoma | Skin Lesion | Moles

United Kingdom
Orlucent, Inc
Hadassah Medical Organization

Completed

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Skin Lesion

Israel
Nordic MDS Group

Unknown

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Sweden
Novartis Pharmaceuticals

Terminated

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

High Risk MDS

United States
Nordic MDS Group

Completed

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Denmark, Norway, Sweden
Groupe Francophone des Myelodysplasies
Novartis

Unknown

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS (GFM-EXVD-AZA)

MDS

France, Belgium
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Gastro Intestinal Surgery and Liver Transplantation; The Hepato-Oncology Group...

Completed

Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Liver Cancer

Italy
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
Alberta Health Services, Calgary
Centre for Aging and Brain Health Innovation; Catalyst Healthcare Ltd.

Completed

Connected Healthcare for Individuals Living at Home With Chronic Conditions

Hypertension | Diabetes | Arthritis | Chronic Pain | Asthma | Medication Adherence | Anxiety Depression | Medication Compliance | Medication Nonadherence

Canada
GWT-TUD GmbH

Recruiting

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA)

AML | MDS

Germany, Austria
Groupe Francophone des Myelodysplasies

Completed

CPX-351 in Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Cooperative Study Group A for Hematology

Unknown

Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation (RICandDLI)

Myelodysplastic Syndrome

Korea, Republic of
Jasper Therapeutics, Inc.

Recruiting

JSP191 (Briquilimab) in Subjects With LR-MDS

Lower-risk Myelodysplastic Syndrome

United States
Groupe Francophone des Myelodysplasies

Unknown

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Myelodysplastic Syndromes

France
Stanford University
Notable Labs Inc.

Active, not recruiting

Biologically Focused Therapy of Treatment-Refractory MDS Patients

Myelodysplastic Syndromes

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
Assiut University

Unknown

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

MDS
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
Helsinn Healthcare SA

Terminated

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Yale University

Withdrawn

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

MDS

United States
University of California, San Francisco
University of California, Los Angeles; University of California, Davis; University... and other collaborators

Recruiting

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing (OPTICS)

Uveitis | Infectious Disease

United States
Centaur Pharmaceuticals

Completed

Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

HIV Infections | AIDS Dementia Complex

United States
Johann Wolfgang Goethe University Hospital

Unknown

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (PANOBEST)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany
Genzyme, a Sanofi Company

Completed

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia (AML)

United States
Mikkael Sekeres, MD
Bristol-Myers Squibb; Celgene

Recruiting

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Myelodysplastic Syndromes

United States
Aplastic Anemia and MDS International Foundation
National Organization for Rare Disorders

Recruiting

Global PNH Patient Registry

Paroxysmal Nocturnal Hemoglobinuria

United States
VIVUS LLC

Completed

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

Erectile Dysfunction

United States
Assiut University

Not yet recruiting

Impulse Control Disorder Among Parkinson's Disease Patients

Parkinson's Disease
University of Leipzig
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients (PRO-RED)

MDS | MDS/MPN

Germany, Austria
Precigen, Inc

Recruiting

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
CytoDyn, Inc.

Completed

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

HIV Infections

United States
Teva Pharmaceuticals USA

Completed

Desmopressin Acetate 0.2 mg Tablets, Fasting

Healthy

Canada
Masonic Cancer Center, University of Minnesota

Completed

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

United States
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
GlaxoSmithKline

Completed

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

Healthy Subjects

United States
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
AbbVie
Genentech, Inc.

Active, not recruiting

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Canada, France, Germany, Italy, United Kingdom
Nordic MDS Group
GlaxoSmithKline

Completed

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) (NMDSG10A)

Thrombocytopenia | Myelodysplastic Syndrome

Sweden
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
Nantes University Hospital

Completed

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)

Search clinical trials for: High Risk Myelodysplastic Syndromes (MDS)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations